• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia.

作者信息

Fleck Caroline, Karabinos Allison, Cook Allene, Moore Donald C, Jacobs Ryan

机构信息

Department of Pharmacy, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

出版信息

Leuk Lymphoma. 2024 Aug;65(8):1198-1199. doi: 10.1080/10428194.2024.2341999. Epub 2024 Apr 22.

DOI:10.1080/10428194.2024.2341999
PMID:38646879
Abstract
摘要

相似文献

1
Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia.评估慢性淋巴细胞白血病患者将奥妥珠单抗从标准输注速率转换为短疗程输注后的安全性结果。
Leuk Lymphoma. 2024 Aug;65(8):1198-1199. doi: 10.1080/10428194.2024.2341999. Epub 2024 Apr 22.
2
Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial.奥滨尤妥珠单抗在中国 B 细胞淋巴瘤患者中的安全性和有效性：GERSHWIN 试验的二次分析。
Cancer Commun (Lond). 2018 May 30;38(1):31. doi: 10.1186/s40880-018-0300-5.
3
Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.维奈托克联合奥滨尤妥珠单抗一线治疗慢性淋巴细胞白血病。
Blood. 2019 Nov 14;134(20):1691-1696. doi: 10.1182/blood.2019001750.
4
Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia.奥比妥珠单抗单药治疗初治慢性淋巴细胞白血病
Leuk Lymphoma. 2018 Sep;59(9):2258-2260. doi: 10.1080/10428194.2017.1410890. Epub 2017 Dec 18.
5
Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience.
Hematol Oncol. 2019 Dec;37(5):641-643. doi: 10.1002/hon.2684. Epub 2019 Nov 7.
6
Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic Leukemia.与奥滨尤妥珠单抗治疗慢性淋巴细胞白血病相关的类甜疹
JAMA Dermatol. 2017 Jan 1;153(1):108-110. doi: 10.1001/jamadermatol.2016.3355.
7
Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab.管理接受奥妥珠单抗治疗的慢性淋巴细胞白血病患者的输液相关反应
Clin J Oncol Nurs. 2016 Apr;20(2):E41-8. doi: 10.1188/16.CJON.E41-E48.
8
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.奥滨尤妥珠单抗单药或联合化疗治疗初治或复发/难治性慢性淋巴细胞白血病患者的安全性和有效性：IIIb 期 GREEN 研究的最终分析。
Br J Haematol. 2021 Apr;193(2):325-338. doi: 10.1111/bjh.17326. Epub 2021 Feb 19.
9
Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia.在使用奥滨尤妥珠单抗治疗慢性淋巴细胞白血病后发生的进行性多灶性白质脑病。
Ann Hematol. 2019 Jun;98(6):1509-1510. doi: 10.1007/s00277-018-3552-x. Epub 2018 Nov 13.
10
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.奥妥珠单抗联合伊布替尼诱导治疗，随后采用微小残留病驱动策略治疗慢性淋巴细胞白血病患者（ICLL07 FILO）：一项单臂、多中心、2期试验。
Lancet Haematol. 2019 Sep;6(9):e470-e479. doi: 10.1016/S2352-3026(19)30113-9. Epub 2019 Jul 16.

引用本文的文献

1
Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study.短期输注奥妥珠单抗联合维奈克拉治疗慢性淋巴细胞白血病：一项前瞻性观察研究。
Blood Neoplasia. 2025 Jan 27;2(2):100075. doi: 10.1016/j.bneo.2025.100075. eCollection 2025 May.
2
[Chinese expert consensus on short duration infusion of obinutuzumab (2024)].《奥妥珠单抗短程输注中国专家共识（2024年版）》
Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):897-901. doi: 10.3760/cma.j.cn121090-20240704-00250.